Lifecore Biomedical, Inc. — Form 8-K Summary
Business context and reporting period
Filed September 29, 2026, reporting an agreement amendment dated September 24, 2026. The filing concerns Lifecore Biomedical, LLC, a subsidiary of Lifecore Biomedical, Inc., and Alcon Research, LLC. The amendment takes effect November 1, 2026.
Financial and operating impact
The 8-K provides no revenue, profit, cash flow, margin, debt, liquidity, or quantified financial impact. It establishes Alcon minimum purchase obligations through 2034 and certain Lifecore supply obligations, but does not state their amounts or detailed terms.
Material change
- Extends the contract’s initial term from December 31, 2031, to December 31, 2034.
- After the initial term, the agreement automatically renews for successive 24-month periods unless either party gives proper notice.
- Beginning November 1, 2026, Lifecore may not enter into new agreements to develop, supply, or manufacture certain products that directly compete with certain Alcon products. Existing agreements may continue and may be renewed, extended, amended, or replaced on substantially similar or more favorable terms for Lifecore.
Outlook, risks, and items to verify
The filing provides no financial guidance or management commentary. The amended purchase and supply commitments, and the scope of the product restriction, could affect future operations; the 8-K does not quantify those effects. The company said the full amendment would be filed as an exhibit to its Form 10-Q for the quarter ended September 30, 2026.
- Review the full amendment for Alcon’s minimum purchase amounts, Lifecore’s supply obligations, and any related conditions.
- Verify which products and activities fall within the restriction on new competing agreements.
- Assess renewal and termination notice provisions in the full agreement.
- Look for any quantified financial or operational effects in the subsequent Form 10-Q.